Scancell(SCLP) , a developer of novel immunotherapies for treating cancer and infectious disease, released its results for the year ended 30 April 2023 as well as a business update on progress achieved post-period.
In the period, operating loss came in at £11.9 million, with R&D spend of £11.6m (FY22: £9.5m). The group's cash balance stood at £19.9 million on April 30, 2023, with a cash runway through to early 2025 achieving the near-term clinical milestones for SCIB1 and Modi-1.
Scancell’s lead ImmunoBody® cancer vaccine, SCIB1, reported positive data from Phase 2 SCOPE trial for advanced melanoma, showing an 82% response rate in combination with checkpoint inhibitors, surpassing expectations. In contrast, patients on doublet CPI therapy alone had a 50% response rate. The trial's second stage is set to finish by 2023's end, aiming for data in H1 2024.
Modi-1 is the lead programme from the Moditope therapeutic vaccine platform. In the period, Modi-1 finished the dose escalation and safety phases of the Phase 1/2 ModiFY trial, progressing into expansion cohorts.
Early patient data revealed Modi-1's favorable safety profile without dose-limiting toxicities during dose escalation. It also exhibited promising efficacy in challenging cancers like head and neck cancer, high grade serous ovarian carcinoma, and triple negative breast cancer. Early clinical data for Modi-1 is expected in 2024.
View from Vox
Scancell is a clinical-stage biopharmaceutical company that specialises in immunotherapy in the treatment of cancer and infectious disease. The types of cancer its products treat include pancreatic cancer - the 5th most common cause of cancer death in the UK - alongside small cell lung cancer and ovarian cancer, to name a few.
The company is building a pipeline of products by utilising its four technology platforms: Moditope and ImmunoBody for vaccines, and GlyMab and AvidiMab for antibodies.
All four of its products - which are at various stages of preclinical and clinical trials - are immunotherapy treatments for cancer. Immunotherapy uses the immune system to fight cancer, helping the immune system recognise and attack cancer cells.
In recent years, immunotherapy has come to be seen as a key part of the clinical management of cancer. In a similar way to how vaccines combat diseases, vaccines are made to identify specific proteins found on specific cancer cells. This helps the immune system to recognise and attack those particular cancer cells.
The benefits of using vaccines for immunotherapy in cancer treatment are immense, with very good specificity, low toxicity, and the potential for a durable treatment effect due to immunologic memory.
Follow Scancell for more News and Updates: